Long-term outcome of atrophic body gastritis has not yet been defined.
Dr Annibale and colleagues from Italy investigated the occurrence of neoplastic lesions in atrophic body gastritis patients.
The research team also assessed at long-term follow-up the behavior of atrophy and intestinal metaplasia.
The team studied 106 atrophic body gastritis patients with 4-year follow-up, separated into 3 groups.
The researchers reported that Group A included 38 patients with Helicobacter pylori-positive at histology and serology and cured of infection.
Group B included 36 patients that were H pylori-positive at serology and not treated and 32 in Group C were H pylori-negative.
|At follow-up, 8% developed neoplastic lesions including adenocarcinoma|
|Alimentary Pharmacology & Therapeutics|
Of these patients, 3 underwent gastroscopy with antral and 3 body biopsies for histology according to the Sydney System.
The team found that at 7-year follow-up body atrophy and intestinal metaplasia remained unchanged in all 106 patients irrespective of H pylori status.
Antral atrophy was significantly increased at follow-up only in Group C, whereas antral intestinal metaplasia was unchanged in all 3 groups.
During follow-up, the team noted that 8% developed neoplastic lesions.
Of those that developed neoplastic lesions, 1 had adenocarcinoma, 1 had adenoma with low-grade dysplasia and 6 had low-grade dysplasia without endoscopic lesions.
The researchers observed that antral atrophic gastritis was present at baseline in all but 1 of the 8 patients with neoplastic lesions.
The team noted that antral atrophic gastritis was present only in 15 of the 98 patients without neoplastic lesions.
Dr Annibale's team concludes, “Atrophy and intestinal metaplasia persist at 7-year follow-up and atrophic body gastritis patients with panatrophic gastritis are at increased risk of developing neoplastic lesions.”